All In Biotech

Drug Trial Radar · NCT03088540

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 712 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

712

Actual

Start

May 29, 2017

Primary completion

Apr 18, 2025

Study completion Apr 18, 2025

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Mar 23, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of the study are: * To compare the overall survival (OS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 in ≥50% of tumor cells * To compare the progression-free survival (PFS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic NSCLC whose tumors express PD-L1 in ≥50% of tumor cells The key secondary objective of the study is to compare the objective response rate (ORR) of cemiplimab versus platinum-based chemotherapies

Conditions

  • Carcinoma,Non-Small-Cell Lung
  • Lung Carcinomas, Non-Small-Cell
  • Non-small-cell Lung Carcinoma
  • Nonsmall Cell Lung Cancer

Interventions

  • PemetrexedDrug

    Patients will be administered pemetrexed chemotherapy as per protocol with either cisplatin or carboplatin

  • PaclitaxelDrug

    Patients will be administered paclitaxel chemotherapy as per protocol with either cisplatin or carboplatin

  • GemcitabineDrug

    Patients will be administered gemcitabine chemotherapy as per protocol with either cisplatin or carboplatin

  • CisplatinDrug

    Administered with either Pemetrexed, Paclitaxel or gemcitabine.

  • CarboplatinDrug

    Administered with either Pemetrexed, Paclitaxel or gemcitabine.

  • cemiplimabDrug

    Patients will be administered cemiplimab as per protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to 94 months
  2. Progression-free Survival (PFS) Per Blinded IRCTime frame: Up to 94 months

Locations

192 sites in 24 countries. Site status is shown where the registry gives one.

  • Clinical Study Site

    Fitzroy, Australia

  • Clinical Study Site

    Albury, New South Wales, Australia

  • Clinical Study Site

    Wollongong, New South Wales, Australia

  • Clinical Study Site

    Minsk, Belarus

  • Clinical Study Site

    Mogilev, Belarus

  • Clinical Study Site

    Barretos, Brazil

  • Clinical Study Site

    Curitiba, Brazil

  • Clinical Study Site

    Joinville, Brazil

  • Clinical Study Site

    Lajeado, Brazil

  • Clinical Study Site

    Mogi das Cruzes, Brazil

  • Clinical Study Site

    Passo Fundo, Brazil

  • Clinical Study Site

    Pelotas, Brazil

  • Clinical Study Site 2

    Porto Alegre, Brazil

  • Clinical Study Site 3

    Porto Alegre, Brazil

  • Clinical Study Site

    Recife, Brazil

  • Clinical Study Site

    Rio de Janeiro, Brazil

  • Clinical Study Site

    Salvador, Brazil

  • Clinical Study Site

    Santa Cecília, Brazil

  • Clinical Study Site

    São José do Rio Preto, Brazil

  • Clinical Study Site #3

    São Paulo, Brazil

  • Clinical Study Site #4

    São Paulo, Brazil

  • Clinical Study Site 1

    São Paulo, Brazil

  • Clinical Study Site 2

    São Paulo, Brazil

  • Clinical Study Site 1

    Porto Alegre, Rio Grande do Sul, Brazil

  • Clinical Study Site

    Dobrich, Bulgaria

  • Clinical Study Site

    Gabrovo, Bulgaria

  • Clinical Study Site

    Recoleta, Chile

  • Clinical Study Site

    Santiago, Chile

  • Clinical Study Site

    Temuco, Chile

  • Clincial Study Site

    Viña del Mar, Chile

  • Clinical Study Site

    Guangdong, China

  • Clinical Study Site

    Harbin, China

  • Clinical Study Site

    Linyi, China

  • Clinical Study Site 1

    Shanghai, China

  • Clinical Study Site 2

    Shanghai, China

  • Clinical Study Site 1

    Tianjin, China

  • Clinical Study Site 2

    Tianjin, China

  • Clinical Study Site

    Xuzhou, China

  • Clinical Study Site

    Zhejiang, China

  • Clinical Study Site

    Lanshan, Shandong, China

Showing 40 of 192 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.